{"entity":{"id":"nct06952504","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan","aka":[],"tldr":"A phase 3 trial of Pembrolizumab, Carboplatin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) is a phase 3 interventional study registered as NCT06952504 by Merck Sharp & Dohme LLC, with 1123 participants planned, started 2025-05-22 and due to reach its primary completion in 2032-05-24. Interventions recorded: Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06952504","url":"https://clinicaltrials.gov/study/NCT06952504"}],"tags":["ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","carboplatin","paclitaxel","docetaxel","sacituzumab-tirumotecan","cisplatin"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06952504","phase":"3","setting":"A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)","sponsor":"Merck Sharp & Dohme LLC","enrolled":1123,"outcomes":[]},"route":"/trials/nct06952504/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}